Hematologic Malignancies
Avencell Therapeutics Inc. focuses its clinical research on aggressive blood cancers, with activity in acute myeloid leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma as well as chronic lymphocytic leukaemia.
- Acute myeloid leukemia
- Relapsed/refractory B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukaemia
The sponsor’s portfolio is centered on difficult-to-treat hematologic cancers where new cellular therapies are being explored.
CAR-T Cell Therapy
The company is active in CAR-T cell therapy research, including work on allogeneic quad-specific CAR-T approaches designed for B-cell malignancies.
- Allogeneic CAR-T platforms
- Quad-specific CAR constructs
- B-cell cancer targeting
Its research interest extends to cellular immunotherapies intended for patients with limited treatment options in blood cancers.
Immuno-Oncology
Avencell Therapeutics Inc. is engaged in immuno-oncology programs that examine how engineered immune cells can be applied to resistant and recurrent malignancies.
- Engineered immune-cell therapies
- Therapies for refractory disease
- Cell-based anticancer strategies
These activities reflect a therapeutic emphasis on redirecting immune function against leukemia and lymphoma.
Long-Term Cellular Therapy Follow-Up
The sponsor also supports follow-up research in cell therapy, with attention to longer-term clinical outcomes after treatment with CAR-T products.
- Long-term safety monitoring
- Durability of response
- Post-treatment outcomes
This area of interest aligns with ongoing evaluation of persistent effects in patients treated for hematologic malignancies.
